William Blair reiterated their buy rating on shares of PTC Therapeutics (NASDAQ:PTCT) in a research note released on Tuesday. William Blair also issued estimates for PTC Therapeutics’ Q4 2018 earnings at ($0.34) EPS, FY2018 earnings at ($1.85) EPS, Q1 2019 earnings at ($0.57) EPS, Q2 2019 earnings at ($0.38) EPS, Q3 2019 earnings at ($1.05) EPS, Q4 2019 earnings at $0.00 EPS, FY2019 earnings at ($2.01) EPS and FY2020 earnings at ($1.67) EPS.
“We show reported earnings, our estimates, and consensus in exhibit 1.”,” William Blair’s analyst commented.
Several other equities research analysts have also recently issued reports on the company. Zacks Investment Research cut PTC Therapeutics from a hold rating to a sell rating in a research note on Friday, October 19th. Bank of America upgraded shares of PTC Therapeutics from an underperform rating to a neutral rating in a research report on Wednesday, October 3rd. Credit Suisse Group set a $55.00 price objective on shares of PTC Therapeutics and gave the company a buy rating in a research report on Wednesday, October 3rd. Cantor Fitzgerald initiated coverage on shares of PTC Therapeutics in a research report on Monday, October 1st. They set an overweight rating and a $66.00 price objective for the company. Finally, JPMorgan Chase & Co. boosted their price objective on shares of PTC Therapeutics to $51.00 and gave the company a neutral rating in a research report on Friday, September 28th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company’s stock. PTC Therapeutics currently has a consensus rating of Buy and a consensus price target of $46.25.
Shares of PTCT stock traded down $2.54 during trading on Tuesday, hitting $33.76. The company had a trading volume of 613,911 shares, compared to its average volume of 682,113. The company has a current ratio of 2.73, a quick ratio of 4.18 and a debt-to-equity ratio of 0.37. The stock has a market cap of $1.84 billion, a P/E ratio of -16.71 and a beta of 2.21. PTC Therapeutics has a one year low of $14.87 and a one year high of $52.95.
PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.66). The company had revenue of $53.59 million during the quarter, compared to the consensus estimate of $70.56 million. PTC Therapeutics had a negative net margin of 30.61% and a negative return on equity of 27.95%. The company’s quarterly revenue was up 28.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.82) earnings per share. Analysts forecast that PTC Therapeutics will post -1.92 EPS for the current year.
Institutional investors and hedge funds have recently made changes to their positions in the business. Meeder Asset Management Inc. acquired a new position in PTC Therapeutics during the second quarter valued at approximately $137,000. Lourd Capital LLC acquired a new position in PTC Therapeutics during the third quarter valued at approximately $202,000. Xact Kapitalforvaltning AB acquired a new position in PTC Therapeutics during the second quarter valued at approximately $216,000. Quantitative Systematic Strategies LLC acquired a new position in PTC Therapeutics during the second quarter valued at approximately $218,000. Finally, CAPROCK Group Inc. acquired a new position in PTC Therapeutics during the second quarter valued at approximately $222,000. Institutional investors and hedge funds own 85.72% of the company’s stock.
PTC Therapeutics Company Profile
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and Emflaza (deflazacort) for treating Duchenne muscular dystrophy.
Further Reading: Trading Strategy
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.